Analyst Price Targets — LIVN
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| July 15, 2026 11:26 am | — | Mizuho Securities | $95.00 | $79.12 | TheFly | LivaNova price target raised to $95 from $90 at Mizuho |
| June 22, 2026 9:44 am | — | KeyBanc | $92.00 | $78.50 | TheFly | LivaNova price target raised to $92 from $83 at KeyBanc |
| May 7, 2026 11:15 am | — | Mizuho Securities | $90.00 | $66.26 | TheFly | LivaNova price target raised to $90 from $85 at Mizuho |
| May 7, 2026 9:33 am | — | Barclays | $76.00 | $66.26 | TheFly | LivaNova price target raised to $76 from $73 at Barclays |
| February 25, 2026 8:54 pm | — | Stifel Nicolaus | $80.00 | $70.29 | TheFly | LivaNova price target raised to $80 from $70 at Stifel |
| February 25, 2026 5:09 pm | Mike Matson | Needham | $81.00 | $70.29 | StreetInsider | Livanova (LIVN) PT Raised to $81 at Needham |
| February 19, 2026 1:24 pm | Adam Maeder | Piper Sandler | $85.00 | $67.33 | StreetInsider | Piper Sandler on Livanova (LIVN): 'Favorite SMID Value Name On Our List' |
| January 9, 2026 12:21 pm | — | Barclays | $67.00 | $64.95 | TheFly | LivaNova price target raised to $67 from $58 at Barclays |
| January 9, 2026 10:50 am | David Roman | Goldman Sachs | $66.00 | $64.95 | TheFly | LivaNova price target raised to $66 from $56 at Goldman Sachs |
| December 19, 2025 1:01 am | Brett Fishbin | KeyBanc | $81.00 | $62.08 | TheFly | LivaNova initiated with an Overweight at KeyBanc |
Latest News for LIVN
GenAI creates new opportunities for ISRG, ALC and LIVN, even as regulatory, inflation and industry headwinds continue to pressure MedTech.
LivaNova (LIVN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
LONDON--(BUSINESS WIRE)---- $LIVN #OSA--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its second-quarter 2026 results on Wed., Aug. 5, 2026, at 1 p.m. London time (8 a.m. Eastern Daylight Time). The Company will release its second-quarter 2026 results prior to the call. The audiocast will be accessible at www.livanova.com/events. Listeners should log…
LIVN's PolySync data show an 84.5% AHI response rate in OSA patients, building on OSPREY results for its aura6000 System.
LONDON--(BUSINESS WIRE)---- $LIVN #OSA--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced new data showing that use of its PolySync™ programming algorithm increased the cumulative apnea-hypopnea index (AHI) response rate to 84.5% in patients with moderate to severe Obstructive Sleep Apnea (OSA) when treated with proximal hypoglossal nerve stimulation (pHGNS). The findings were…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for LIVN.
U.S. House Trading
No House trades found for LIVN.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.